【摘要】 目的:探讨精神分裂症患者使用齐拉西酮治疗时血药浓度与疗效的关系及对代谢指标的影响。方法:55例精神分裂症患者分别给予齐拉西酮120 mg/d(18例)和160 mg/d(37例)治疗,疗程6周。采用高效液相色谱法分别于治疗1、2、6周测定齐拉西酮的血浆药物浓度;同时予阳性与阴性症状量表(PANSS)评估疗效;对血药浓度与疗效相关性进行分析比较。结果:治疗6周,使用齐拉西酮120 mg/d治疗的18例患者平均血药浓度为(191.9±86.0)ng/ml,PANSS总分较基线降低(15.0±1.2)分,减分率38%;血药浓度与PANSS总分减分率呈明显正相关(r=0.435,P<0.05)。使用齐拉西酮160 mg/d治疗的37例患者平均血药浓度为(271.4±22.0)ng/ml,PANSS总分较基线降低(32.0±3.0)分,减分率43%;血药浓度与PANSS总分减分率呈显著正相关(r=0.383,P<0.05)。未发现对代谢指标有不良影响。结论:齐拉西酮治疗精神分裂症血药浓度与疗效相关,且血药浓度(271.4±22.0)ng/ml时疗效最好。更多还原

【Abstract】 Objective: To explore the correlation of the plasma concentration of ziprasidone with the treatment effect and metabolism index in treatment of patients with schizophrenia. Method: fifty-five patients with schizophrenia were enrolled in this study. 18 patients took 120 mg / day and 37 patients 160 mg / day of ziprasidone for 6 weeks. Plasma concentrations of ziprasidone were tested using high efficiency liquid chromatography,and positive and negative syndrome scale( PANSS) was administered at baseline,week 1,week 2 and week 6. Results: After 6 weeks treatment,the 18-patients( 120 mg / day of ziprasidone) group had mean serum ziprasidone concentration of( 191. 9 ± 86. 0) ng / ml. Compared with the baseline,the PANSS score decreased by 38%,the PANSS score was( 15. 0 ± 1. 2). The serum ziprasidone concentration was significantly positively correlated with the decrease rate of PANSS score( r = 0. 435,P < 0. 05). Mean serum ziprasidone concentration in 37-patients group(( 160 mg / day of ziprasidone) was( 271. 4 ± 22. 0) ng / ml,and the PANSS score was( 32. 0 ± 3. 0),which was 43% less than the score at baseline. Serum ziprasidone concentration and the decrease rate of PANSS score was significantly positively correlated( r = 0. 383,P < 0. 05). No obvious side effects were found especially metabolic index. Conclusion: The plasma concentration of ziprasidone is correlated with curative efficacy,the plasma concentration of( 271. 4 ± 22. 0) ng / ml may have the best effect.更多还原